News - CD4 expression

19h

Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells. (PubMed, J Immunother Cancer)

Collectively, our findings shed light on the discovery of a new multitarget inhibitor able to induce ICD and MHC-II upregulation in TC-1 tumor cell. These two processes participate in enhancing a specific CD4+ cytotoxic T cell-mediated antitumor response in vivo in our model of lung cancer. This breakthrough suggests the potential of QAPHA as a promising agent for cancer treatment.

19 hours ago

Journal • IO biomarker

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • CALR (Calreticulin) • CRTAM (Cytotoxic And Regulatory T Cell Molecule) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • NKG2D (killer cell lectin like receptor K1)

MHC-II expression • CD4 expression

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P1, N=55, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Terminated due to slow enrollment and end of funding

8 days ago

Trial termination • CAR T-Cell Therapy

BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • SELL (Selectin L)

CD19 positive • CD8 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative • CD4 expression

cyclophosphamide • fludarabine IV • JCAR014

17d

Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy. (PubMed, Front Immunol)

Both CD4+ and CD8+ T cell subsets, transduced with HPV16-E7 specific transgenic TCR, demonstrated cytotoxic features after exposure to HPV-16 E7-derived antigen. Ultimately, the presence of such atypical T cells, either mismatched MHC II-restricted TCR/CD8+ T cells or cytotoxic CD4+ T cells, is likely to influence the fate of patient-infused T cell product and would need further investigation.

17 days ago

Preclinical • Journal

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL15 (Interleukin 15) • IL7 (Interleukin 7)

CD8 expression • CD4 expression

18d

Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes. (PubMed, Front Immunol)

Our findings demonstrate that IL-38 expression in colorectal regional nodes from CRC patients is inversely correlated with PD-1/PD-L1 but positively correlated with infiltrating CD4+ or CD8+ lymphocytes. The combined assessment of IL-38 and PD-1 expression in colorectal regional nodes emerges as a promising biomarker for predicting the prognosis of CRC.

18 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)

PD-1 expression • CD8 expression • CD4 expression • PD-1 underexpression

27d

FaCIL-2: Low-dose Interleukin-2 in Women With Unexplained Miscarriages (clinicaltrials.gov)

P1/2, N=18, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Trial primary completion date: Feb 2024 --> Jul 2023 | Trial completion date: Feb 2025 --> Apr 2024

27 days ago

Trial completion date • Trial primary completion date

CD4 (CD4 Molecule) • IL2 (Interleukin 2)

CD4 expression

29d

CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness. (PubMed, Sci Adv)

Genetic depletion of CD4+ T regulatory cells abolishes the immunorestrictive and protumorigenic effects of CKLF. Our work supports that disrupting CKLF-mediated cross-talk between tumor and CD4+ suppressor cells represents a promising immunotherapeutic approach to battling MYCN-driven tumors.

29 days ago

Journal

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule)

CD4 expression

Monomorphic epitheliotropic T-cell lymphoma with strong CD4 expression. (PubMed, Blood)

No abstract available

1 month ago

Journal

CD4 (CD4 Molecule)

CD4 expression

Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer. (PubMed, Clin Transl Oncol)

Our research has yielded encouraging results in identifying a correlation between immunotherapy's response and clinical characteristics, peripheral immune cell subsets, and biochemical and immunological biomarkers. The screened hematological detection panel could be used to forecast an NSCLC patient's response to anti-PD-1 immunotherapy with an accuracy rate of 76.3%, which could help customize suitable therapeutic decision-making.

1 month ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

CD8 expression • CD4 expression

2ms

Predicting the mechanism of action of YQYYJD prescription in the treatment of non-small cell lung cancer using transcriptomics analysis. (PubMed, J Ethnopharmacol)

YQ was the key disassembled prescription of YQYYJD, exerting significant antitumor effects and immune regulation effects on NSCLC. It may have relieved T cell exhaustion and regulated the immune microenvironment to exert antitumor effects by changing lung cancer-related targets, pathways, and biological processes.

2 months ago

Journal

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CASP3 (Caspase 3)

CD8 expression • IFNG expression • CD4 expression • IL2 expression

2ms

LAG-3- and CXCR5-expressing CD4 T cells display progenitor-like properties during chronic visceral leishmaniasis. (PubMed, Cell Rep)

The transcriptional repressor B cell lymphoma-6 was partially required for their maintenance. Altogether, we propose that the LAG3+CXCR5+ CD4 T cell subset could play a role in maintaining CD4 T cell responses during persistent infections.

2 months ago

Journal • IO biomarker

LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • RAG1 (Recombination Activating 1)

LAG3 expression • CD4 expression • CXCR5 expression

2ms

Evaluating CD4 and Foxp3 mRNA Expression in Tissue Specimens of Celiac Disease and Colorectal Cancer Patients. (PubMed, Asian Pac J Cancer Prev)

This study reveals differential expression patterns of CD4 and Foxp3 mRNA in CRC and CD patients. Upregulated CD4 mRNA suggests its potential role in promoting tumor growth, while increased Foxp3 mRNA expression may reflect an immunosuppressive mechanism in CD pathogenesis. These findings provide insights into the molecular and immunological aspects of CRC and CD, warranting further studies for potential therapeutic strategies.

2 months ago

Journal

CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)

CD4 expression • FOXP3 expression

2ms

Kidney double positive T cells have distinct characteristics in normal and diseased kidneys. (PubMed, Sci Rep)

We studied kidney DPT cells in mice at baseline and after ischemia reperfusion (IR) and cisplatin injury...DPT cells constituted a minor population in both normal and cancer portion of human kidneys. In conclusion, DPT cells constitute a small population of mouse and human kidney T cells with distinct inflammatory and metabolic profile at baseline and following kidney injury.

2 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • IL17A (Interleukin 17A) • CPT1A (Carnitine Palmitoyltransferase 1A) • SLC2A1 (Solute Carrier Family 2 Member 1)

PD-1 expression • CD8 expression • CD4 expression

cisplatin

2ms

OCA-B/Pou2af1 is sufficient to promote CD4+ T cell memory and prospectively identifies memory precursors. (PubMed, Proc Natl Acad Sci U S A)

We show that early in viral infection, endogenously elevated OCA-B expression prospectively identifies memory precursor cells with increased survival capability and memory recall potential. Cumulatively, the results demonstrate that OCA-B is both necessary and sufficient to promote CD4 T cell memory in vivo and can be used to prospectively identify memory precursor cells.

2 months ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule) • IL7R (Interleukin 7 Receptor) • SOCS2 (Suppressor Of Cytokine Signaling 2) • GADD45B (Growth Arrest And DNA Damage Inducible Beta) • POU2AF1 (POU Class 2 Homeobox Associating Factor 1) • TCF7 (Transcription Factor 7)

BCL2 expression • CD4 expression • SOCS2 expression

2ms

Canine T zone lymphoma is a tumor of mature, previously activated αβ T cells. (PubMed, Vet Immunol Immunopathol)

TZL cells do not proliferate when stimulated through the T cell receptor but will divide when the T cell receptor is bypassed with PMA and ionomycin. The observation that these cells are derived from a mature, previously activated T cell is the first step in understanding the genesis of this unique T cell tumor.

2 months ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • GATA3 (GATA binding protein 3)

CD8 expression • PTPRC expression • CD4 expression

2ms

Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma. (PubMed, Eur Urol Oncol)

Although most patients exhibit a poor response to Pem, individuals with low FGFR3 expression and immune hot status may benefit clinically from Pem treatment.

2 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • MSR1 (Macrophage Scavenger Receptor 1)

FGFR3 mutation • CD8-H • FGFR3 expression • CD4 expression

Keytruda (pembrolizumab)

3ms

Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma. (PubMed, Cells)

Anti-CCR4 antibodies enhanced the cytotoxic activity of the γδ T cells and NK cells against HTLV-1-infected CCR4-expressing CD4 T cells in an antibody concentration-dependent manner. Taken together, the adoptive transfer of γδ T cells and NK cells expanded with PTA/IL-2/IL-18 is a promising alternative therapy for ATL.

3 months ago

Journal • Immune cell

CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL18 (Interleukin 18)

CD4 expression

3ms

Single institution study of the immune landscape for canine oral melanoma based on transcriptome analysis of the primary tumor. (PubMed, Front Vet Sci)

This preliminary study reports significant changes in gene expression for oral melanoma between canine patients with localized disease relative to those with metastatic disease. In the future, a more in-depth investigation involving immunohistochemistry analysis and single-cell RNA expression is necessary to confirm our findings.

3 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • BCL2 (B-cell CLL/lymphoma 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • ANXA1 (Annexin A1) • IL18 (Interleukin 18) • TLR4 (Toll Like Receptor 4) • TP63 (Tumor protein 63) • CEACAM1 (CEA Cell Adhesion Molecule 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)

BCL2 expression • TIGIT expression • VEGFA expression • CD4 expression

3ms

IFNγ drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy. (PubMed, Acta Neuropathol Commun)

Results from these studies indicate that IFNγ expression from CD4+ T cells drives α-syn-mediated neuroinflammation, demyelination, and neurodegeneration. These results indicate that targeting IFNγ expression may be a potential disease modifying therapeutic strategy for MSA.

3 months ago

Preclinical • Journal

IFNG (Interferon, gamma) • CD4 (CD4 Molecule)

IFNG expression • CD4 expression

3ms

Role of Inflammatory Markers in Sepsis (clinicaltrials.gov)

P=N/A, N=60, Recruiting, National Cancer Institute, Egypt | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL17A (Interleukin 17A) • ISG20 (Interferon Stimulated Exonuclease Gene 20)

IL2RA expression • CD4 expression

3ms

Targeting TIGIT for cancer immunotherapy: recent advances and future directions. (PubMed, Biomark Res)

Although two clinical studies on advanced lung cancer had positive results, the TIGIT-targeted antibody, tiragolumab, recently failed in two new trials. In this review, we highlight the current developments on TIGIT for cancer immunotherapy and discuss the characteristics and functions of TIGIT.

3 months ago

Review • Journal

CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule)

CD8 expression • CD4 expression

tiragolumab (RG6058)

3ms

E3 ubiquitin ligase casitas B-lineage lymphoma-b modulates T-cell anergic resistance via phosphoinositide 3-kinase signaling in patients with immune thrombocytopenia. (PubMed, J Thromb Haemost)

CD4 T cells from patients with ITP showed resistance to anergic induction, highly activated phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) signaling, decreased CBLB expression, and 5' UTR hypermethylation of CBLB. CBLB overexpression in T cells effectively attenuated the elevated p-AKT level and resistance to anergy. Low-dose decitabine treatment led to significantly elevated CBLB expression in CD4 T cells from seven patients showing a partial or complete response. These results indicate that the 5' UTR hypermethylation of CBLB in CD4 T cells induces resistance to T-cell anergy in ITP. Thus, the upregulation of CBLB expression by low-dose decitabine treatment may represent a potential therapeutic approach to ITP.

3 months ago

Journal

CD4 (CD4 Molecule) • CBLB (Cbl Proto-Oncogene B)

CD4 expression

decitabine

4ms

SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer. (PubMed, Hum Genomics)

Our study shows that the SPP1 gene might be an effective biomarker for predicting the prognosis and the efficacy of immunotherapy in PSCC patients.

4 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CD4 (CD4 Molecule)

PD-L1 expression • CD4 expression • SPP1-L

4ms

Correction: MDR1-expressing CD4+ T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical response. (PubMed, J Immunother Cancer)

No abstract available

4 months ago

Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CD4 (CD4 Molecule)

CD4 expression

4ms

The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma. (ASCO-GU 2024)

This study found that BAP1 and cytokines, cAMP pathway and immune inflammation-related pathways were significantly enriched at the transcriptome level. IHC results suggested that LAG3 was more highly expressed in patients with BAP1 mutation. Clinical treatment analysis found that PD-1 inhibitor-based immune combination therapy is not effective for patients with BAP1 mutations.

4 months ago

PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)

PD-L1 expression • PBRM1 mutation • BAP1 mutation • CD8 expression • LAG3 expression • CD4 expression

4ms

Integrative analysis of single-cell and bulk RNA seq to reveal the prognostic model and tumor microenvironment remodeling mechanisms of cuproptosis-related genes in colorectal cancer. (PubMed, Aging (Albany NY))

The current investigation has developed a prognostic framework utilizing cuproptosis-related genes that is highly effective in predicting prognosis, TME type, and response to immunotherapy in CRC patients. Furthermore, our study reveals a novel finding that elevated levels of COX17 expression within CD4-CXCL13 T cells in CRC mediates T cell exhaustion and Treg infiltration, while DLAT has been found to facilitate the anti-tumor immunity activation through the T cell exhaustion reversal and the induction of pyroptosis.

4 months ago

Journal • IO biomarker

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • DLAT (Dihydrolipoamide S-Acetyltransferase)

CD4 expression

4ms

GPR15 in colon cancer development and anti-tumor immune responses. (PubMed, Front Oncol)

Consistent with a protective role of GPR15, administration of GPR15L to established tumors in the MC38-CRC model increased CD45 cell infiltration, enhanced TNFa expression on CD4+ and CD8+ T cells at the tumor site and dramatically reduced tumor burden. Our findings highlight an important, unidentified role of the GPR15-GPR15L axis in promoting a tumor-suppressive immune microenvironment and unveils a novel, colon-specific therapeutic target for CRC.

4 months ago

Journal

CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL17A (Interleukin 17A)

CD8 expression • CD4 expression

4ms

Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression. (PubMed, Sci Rep)

Cytological experiments further showed that aspirin could inhibit the proliferation and PD-L1 expression in Hep G2 and Hep 3B cells. In conclusion, aspirin can inhibit the proliferation of HCC cells and reduce tumor burden by reducing inflammation and targeting PD-L1.

4 months ago

Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

PD-L1 expression • CD4 expression

4ms

Association of WHSC1/NSD2 and T-cell infiltration with prostate cancer metastasis and prognosis. (PubMed, Sci Rep)

Importantly, a new immune classification based on NSD2 expression and CD4 TILs and CD8 TILs was successfully used to stratify PCa patients based on OS.PSA and CD4 TILs are independent risk factors for PCa bone metastasis. This study demonstrates a novel role for NSD2 in defining immune infiltrate on in PCa and highlights the great potential for its application in immunotherapy response evaluation for prostate malignancies.

4 months ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)

CD4 expression

4ms

Genomics and transcriptomics of pancreatic adenosquamous carcinoma. (ASCO-GI 2024)

This is the largest molecular profiling analysis of PASC, which is characterized by unique genomic alterations, and is associated with higher PD-L1 expression, immune related gene expression, CD4+ T cell infiltration and IFN gamma signature, and lower MAPK activation. PASC is associated with better OS compared to PSCC. These findings may provide subtype-specific therapeutic opportunities for PASC and PSCC pts.

4 months ago

PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SF3B1 (Splicing Factor 3b Subunit 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CASP8 (Caspase 8) • HMGA2 (High mobility group AT-hook 2) • AXIN1 (Axin 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • BCL9 (BCL9 Transcription Coactivator) • ZNF384 (Zinc Finger Protein 384)

PD-L1 expression • TMB-H • MSI-H/dMMR • PTEN mutation • ROS1 fusion • SF3B1 mutation • CTLA4 expression • AKT2 amplification • CD4 expression

MI Tumor Seek™

4ms

Regulation of the STAT3 pathway by lupus susceptibility gene Pbx1 in T cells. (PubMed, Mol Immunol)

Pbx1 deficiency also increased the expression of cell cycle arrest and pro-apoptotic genes, with an increased apoptosis in T cells. Our results suggest a complex interplay between PBX1 and STAT3, which may contribute to lupus pathogenesis through dysregulation of the cell cycle and apoptosis.

4 months ago

Journal

STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • PBX1 (PBX Homeobox 1)

STAT3 expression • CD4 expression • STAT3 overexpression

5ms

Profile and immune environment of upper tract urothelial carcinoma (PubMed, Prog Urol)

This exploratory work highlighted that PD1 was the most represented checkpoint. TIGIT was the second most represented checkpoint while ICOS, TIM3 and LAG3 were 3 other checkpoints whose expression was found to be less important. ILT2 and OX40 appeared to be weakly expressed.

5 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator)

LAG3 expression • HAVCR2 expression • TIGIT expression • CD4 expression

5ms

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL (clinicaltrials.gov)

P1/2, N=30, Completed, University Children's Hospital Tuebingen | Unknown status --> Completed | Trial completion date: Aug 2021 --> Dec 2023

5 months ago

Trial completion • Trial completion date

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

CD8 expression • CD4 expression

Zyclara (imiquimod)

5ms

Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer. (PubMed, Front Immunol)

To our knowledge, this is the first study that shows which of the innate and adaptive immune biomarkers are activated during PDT related treatment of the TNBC 4T1 mouse models. The results also indicate that some of the immune response biomarkers can be used to monitor the effectiveness of PDT treatment in TNBC murine model warranting further investigation in human subjects.

5 months ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CCL5 (Chemokine (C-C motif) ligand 5) • CCL2 (Chemokine (C-C motif) ligand 2) • GZMA (Granzyme A) • BCL3 (BCL3 Transcription Coactivator) • PRF1 (Perforin 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)

BCL2 expression • CD8 expression • CD4 expression

Visudyne (verteporfin)

5ms

Diagnostic Challenges in the Leukemia Phase of Blastic Plasmacytoid Dendritic Cell Neoplasm without Skin Involvement: A Clinical and Pathological Study (ASH 2023)

Only one cycle of decitabine + CAG was given and 5 months later, the disease progressed to the leukemia phase...The latter case had ASXL1 and TET2 mutations detected by NGS analysis, achieved complete remission after receiving venetoclax + azacitidine for one cycle, followed by intermittent venoclax +demethylation agent or low-dose chemotherapy maintenance treatment and live for more than two years now... BPDCN without skin lesions is clinically rare, and its diagnosis is challenging. Comprehensive immunophenotyping and cautious interpretation of immunohistochemistry results such as dim lysozyme expression are crucial. Venetoclax-containing regimens have shown promising therapeutic effects.

5 months ago

Clinical

TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD36 (thrombospondin receptor) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NRP1 (Neuropilin 1) • SPN (Sialophorin) • TCL1A (TCL1 Family AKT Coactivator A) • ANPEP (Alanyl Aminopeptidase, Membrane) • CLEC4C (C-Type Lectin Domain Family 4 Member C) • MPO (Myeloperoxidase)

TP53 mutation • ASXL1 mutation • TET2 mutation • CD123 positive • NCAM1 expression • CD123 expression • CD4 expression • IDH2 mutation + TP53 mutation • IL3RA positive • NCAM1 positive

Venclexta (venetoclax) • azacitidine • decitabine

5ms

Soluble and Membrane P-Glycoprotein Expression in Lymphocytes from Diffuse Large B Cell Non-Hodgkin's Lymphoma Patients Treated with R-CHOP (ASH 2023)

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) has been the first-line therapy for patients with DLBC-NHL since the early 2000s. B-cells affected by rituximab may influence T-cell P-gp expression and this may be the reason why MFI was lower on DLBC-NHL group than control group. This study helps to expand the understanding of P-gp's role in DLBC-NHL patients as well as R-CHOP therapy effects on the expression of the P-gp in circulating T-cells.

5 months ago

Clinical

CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1)

CD8 expression • ABCB1 expression • CD4 expression

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine

5ms

Intermittent Sargramostim Administration Expands Proliferating Naïve T Cells, Tregs, HLA-DR+ PD-L1+ Monocytes and Myeloid-Derived Suppressor Cells: Results from a Randomized Placebo-Controlled Clinical Trial of GM-CSF in Patients with Peripheral Artery Disease (ASH 2023)

Our findings demonstrate that intermittent dosing with sargramostim is well-tolerated and induces significant but transient increases in the numbers and activation status of T cells in the bloodstream. Sargramostim treatment also increased numbers of proliferating naïve T cells, Tregs, and certain subsets of myelo-monocytic cells with immunosuppressive phenotypes. These results support the use of intermittent sargramostim dosing to avoid excessive leukocytosis and associated adverse effects.

5 months ago

Clinical

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha) • CD14 (CD14 Molecule) • CSF2 (Colony stimulating factor 2) • FOXP3 (Forkhead Box P3)

PD-1 expression • CD8 expression • CD4 expression

Leukine (sargramostim)

5ms

Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation. (PubMed, Front Pharmacol)

These data suggest that PD-L1 Fc recombinant protein decreases the levels of inflammatory cytokines and the proportion of CD4 T cells without exhaustion. The PD-L1-mediated immune checkpoint mechanism was associated with rejection in the murine tracheal transplant model, suggesting a potential novel target for immunotherapy in lung transplantation.

5 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)

CD4 expression

5ms

Effects of metformin therapy on HMGB1 levels in rheumatoid arthritis patients. (PubMed, Eur J Med Res)

The serum HMGB1 levels were significantly increased in RA patients in active phase. The serum levels of HMGB1 and inflammatory factors and VAS scores were decreased gradually with metformin treatment. HMGB1 might act as a novel therapeutic target for RA.

5 months ago

Journal

CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • HMGB1 (High Mobility Group Box 1) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)

CD8 expression • CD4 expression • IL6 expression

methotrexate • metformin • hydroxychloroquine

5ms

CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels. (PubMed, J Cancer Res Clin Oncol)

A threshold effect is shown to exist between the peripheral blood CD4 and distant metastasis in NSCLC patients. It was revealed that the risk of distant metastasis is lower when CD4 is maintained between 32 and 44%, whereas low ( 44) levels of CD4 are associated with an increased risk of distant metastasis in NSCLC patients.

5 months ago

Journal

CD4 (CD4 Molecule)

CD4 expression

5ms

MDR1-EXPRESSING CD4 T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE. (PubMed, J Immunother Cancer)

MDR1 favored the enrichment of Th1.17 and Th17 in blood and tumor after NAC that correlated to clinical response.

5 months ago

Journal

CD8 (cluster of differentiation 8) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CD4 (CD4 Molecule)

CD8 expression • CD4 expression

paclitaxel

5ms

sFgl2 gene-modified MSCs regulate the differentiation of CD4 T cells in the treatment of autoimmune hepatitis. (PubMed, Stem Cell Res Ther)

By promoting Tregs differentiation and inhibiting Th17 and Th1 cell differentiation, sFgl2 gene-modified MSCs have a more powerful therapeutic effect on Con A-induced experimental AIH and may represent a strategy for the clinical treatment of AIH.

5 months ago

Journal

CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3) • SMAD2 (SMAD Family Member 2)

CD4 expression • IL6 expression

5ms

The Relationship Between the Expression of circFAT1 and Immune Cell in Patients with Non-Small Cell Lung Cancer. (PubMed, Int J Gen Med)

Spearman correlation analysis showed that circFAT1 was positively correlated with the expression of CD4+ and Foxp3+ and negatively correlated with the expression of CD8+ (P < 0.05). CircFAT1 is highly expressed in the serum of NSCLC patients and is closely related to immune cells.

5 months ago

Journal • Immune cell

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)

CD8 expression • CD4 expression • FOXP3 expression